SCHEMBL12371639

SCHEMBL12371639

O=c1[nH]c2cnc(NC[C@@H]3CCNC3)nc2n1Cc1cccc(Cl)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.44
PRKCQ Q04759 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
JAK2 O60674 3/20 0.38
JAK3 P52333 2/20 0.38
USP1 O94782 5/20 0.37
BRD4 O60885 1/20 0.35
ATAD2 Q6PL18 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
MAOB P27338 2/20 0.35
HTR6 P50406 2/20 0.35
JAK1 P23458 1/20 0.35
CDK4 P11802 1/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12371667 1.00 KDM1A (0.44) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL12371646 1.00 KDM1A (0.44) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL12371635 0.93 PRKCQ (0.48) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL12371647 0.93 PRKCQ (0.48) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL12371664 0.93 PRKCQ (0.48) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL13608313 0.92 KDM1A (0.43) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL13608117 0.91 KDM1A (0.40) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL12371633 0.90 KDM1A (0.46) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL12371640 0.90 KDM1A (0.46) KDM1APRKCQCYP3A4CYP2C9JAK2
SCHEMBL12371656 0.90 KDM1A (0.46) KDM1APRKCQCYP3A4CYP2C9JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989459-B2 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one PHARMACOPEIA, LLC (US) 2011-08-02 US disclosed
US-7989459-B2 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one PHARMACOPEIA, LLC (US) 2011-08-02 US disclosed
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2009-11-12 US disclosed
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2009-11-12 US disclosed
WO-2008143674-A1 PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2008-11-27 WO disclosed
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-04-10 US disclosed
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PRKCE, PRKCH, PRKCQ KDM1A 1218/4885PRKCQ 3/4885CYP3A4 2523/4885
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PRKCE, PRKCZ, PRKCQ KDM1A 1070/4885PRKCQ 3/4885CYP3A4 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.